Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06246799 · ClinicalTrials.gov registry record · Phase 3
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
A Phase 3 study of Type 2 Diabetes (Adult Onset), sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 256
- Enrollment target
- 2
- Study locations
NCT06246799 is a Phase 3 study of Type 2 Diabetes (Adult Onset) that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 256 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT06246799, a Phase 3 study of Type 2 Diabetes (Adult Onset), is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 256 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Pioglitazone
- DRUG Sitagliptin
- DRUG Metformin HCI XR
Study Locations (2)
Texas
- University Health System Texas Diabetic Institute - San Antonio
- UT Health Science Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2024-11-07 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06246799
The ClinicalTrials.gov registry entry for NCT06246799 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes (Adult Onset) appearing as the primary indexed condition, and to 4 interventions - of which Tirzepatide is the first listed.
NCT06246799 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06246799 about?
NCT06246799 is a clinical study titled "Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes". The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.
What is the current status of trial NCT06246799?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2024-11-07. Estimated completion is 2029-06-30.
What conditions does trial NCT06246799 study?
This clinical trial studies the following conditions: Type 2 Diabetes (Adult Onset).
What interventions are being tested in trial NCT06246799?
The interventions under investigation include: Tirzepatide (DRUG), Pioglitazone (DRUG), Sitagliptin (DRUG), Metformin HCI XR (DRUG).
Who is sponsoring clinical trial NCT06246799?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06246799 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes (Adult Onset)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.